Dova Pharmacuet (NASDAQ:DOVA) is set to release its earnings data after the market closes on Thursday, August 10th. Analysts expect Dova Pharmacuet to post earnings of ($0.24) per share for the quarter.
Dova Pharmacuet (NASDAQ DOVA) opened at 19.91 on Friday. The stock’s market cap is $497.55 million. The firm has a 50 day moving average of $21.73 and a 200-day moving average of $21.73. Dova Pharmacuet has a 12-month low of $16.98 and a 12-month high of $28.59.
Several research analysts have recently issued reports on DOVA shares. Jefferies Group LLC started coverage on shares of Dova Pharmacuet in a report on Monday, July 24th. They issued a “buy” rating and a $30.00 target price for the company. Leerink Swann started coverage on shares of Dova Pharmacuet in a report on Monday, July 24th. They issued a “market perform” rating and a $24.00 target price for the company. Finally, J P Morgan Chase & Co started coverage on shares of Dova Pharmacuet in a report on Monday, July 24th. They issued an “overweight” rating and a $35.00 target price for the company.
In related news, VP Kevin Laliberte bought 6,200 shares of the stock in a transaction dated Wednesday, July 5th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $105,400.00. Following the acquisition, the vice president now owns 6,200 shares in the company, valued at approximately $105,400. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Alex Sapir bought 20,100 shares of the stock in a transaction dated Wednesday, July 5th. The stock was bought at an average price of $17.00 per share, with a total value of $341,700.00. Following the acquisition, the chief executive officer now owns 20,100 shares in the company, valued at approximately $341,700. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 101,800 shares of company stock valued at $1,798,280.
COPYRIGHT VIOLATION WARNING: “Dova Pharmacuet (DOVA) Set to Announce Earnings on Thursday” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/05/dova-pharmacuet-dova-set-to-announce-earnings-on-thursday.html.
About Dova Pharmacuet
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmacuet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmacuet and related companies with MarketBeat.com's FREE daily email newsletter.
